Category: featured

AGILeBiotics has received the Lead Development Voucher from the Netherlands Antibiotic Development Platform

We are proud to announce that AGILeBiotics has been awarded the Lead Development Voucher by the Netherlands Antibiotic Development Platform (NADP). The total amount of €50.000 will be allocated to the pre-clinical R&D activities. With this financial support we will evaluate the in vivo efficacy of our antibiotic candidates in a clinically relevant animal model […]

AGILeBiotics is welcoming new team members

We are proud to announce that AGILeBiotics has expended its Management Team and Scientific Advisory Board. Victor Schut is the new Chief Business Officer, Dr. Frederik Deroose has joined us as expert in pre-clinical development of novel antibiotics, and Prof. Jan Verhoef is now a member of our Scientific Advisory Board. With joined forced we aim to […]

AGILeBiotics became a member of the BEAM Alliance

We are proud to announce that AGILeBiotics is now a member of the BEAM Alliance, the European AMR innovation hub gathering Biopharma companies. Launched in June 2015, the BEAM (Biotech companies in Europe combating AntiMicrobial Resistance) Alliance is a strong Network of approx. 50 small and medium-sized European biopharmaceutical companies committed by developing innovative products to fend-off […]

AGILeBiotics raised next round of investment to advance novel antibiotic candidates into pre-clinical development

Gronigen, The Netherlands. AGILeBiotics BV has raised the next series of investment for the development of novel antibiotics against multidrug-resistant infections. On 18th of July 2018, a deal was closed securing a joined investment from five regional investors, i.e. RUG Houdstermaatschappij BV, Stichting Ir. G.J. Smid Fonds BV, and Hanzepoort BV, Carduso Capital BV and Pharma Connect […]

AGILeBiotics’ drug development is supported by the Versneller Innovatieve Ambities (VIA) – subsidy from Samenwerkingsverband Noord-Nederland (SNN)

Supported by the Versneller Innovatieve Ambities (VIA)-subsidy from Samenwerking Noord-Nederland (SNN), AGILeBiotics is developing novel antibiotics for hospital-treated Gram-negative infections. According to the World Health Organization (WHO) and the Infectious Disease Society of America (IDSA) the world is entering the post-antibiotic era, with no therapy option left for patients infected by multidrug-resistant (MDR) pathogen. Without novel […]

AGILeBiotics joins the Health-i-Care program

AGILeBiotics entered successfully the Health-i-Care program (INTERREG) starting a collaboration with the University Medical Center Groningen (UMCG) and Hospitals in Germany (Muenster and Oldenburg). Health-i-Care is focusing on the development of innovative products and technologies to protect the society from infections caused by resistant microorganisms and to limit the spread of multidrug-resistant bacteria. Thanks to our participation […]

AGILeBiotics acquires first round of equity investment

AGILeBiotics receives a pre-seed investment from three local investors, i.e. RUG Houdstermaatschappij BV Stichting Ir G.J. Smid Fonds BV Hanzepoort BV With this financial support, AGILeBiotics has launched its drug discovery and development program, and envisions advancing first antibiotic candidates into late pre-clinical development in 2018.